Active Specific Immunotherapy

Novel Vaccine Has Potent Anticancer Activity

Published in Vaccine Weekly, October 10th, 2001

Biomira Inc. announced that its lead product candidate, Theratope vaccine, has been reviewed in the September 2001 issue of Ashley Publications' Expert Opinion on Biological Therapy, a United Kingdom bimonthly, peer-reviewed journal.

The authors of the paper are Drs. Leona A. Holmberg and Brenda M. Sandmaier. Holmberg and Sandmaier are clinical researchers at the Fred Hutchinson Cancer Research Center and professors of medicine at the University of Washington in Seattle.

The paper focuses on the concept that Theratope vaccine's synthetic carbohydrate antigen, Sialyl-Tn (STn), "is an ideal candidate for active specific immunotherapy (ASI),"...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (2001-10-10)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry